BioSig Technologies Inc has announced that John Sieckhaus will be joining the company as chief operating officer.
The Westport, Connecticut-based company said that Sieckhaus brings 30 years of experience in the healthcare industry, including 21 years at St Jude Medical and Abbott Laboratories (NYSE:ABT).
“We are pleased to welcome John to the team as we build toward a national rollout of our leading product, PURE EP,” CEO Kenneth L. Londoner said in a statement. “John's leadership experience in the electrophysiology space and his impressive track record in capturing and growing market share in the US is well-aligned with our mission to bring our signal processing technology to as many hospitals as possible in the coming years."
READ: BioSig Technologies receives boost for its PURE EP technology with award of patent claims
During his tenure with St Jude Medical, BioSig said Sieckhaus held commercial leadership positions of increasing responsibility, including US national sales leader, senior vice president and general manager when he led sales and customer relationship management activities in the US across all cardiovascular product lines.
It noted that his experience in building and leading high-performance teams, in addition to integrating multiple new and novel technologies and introducing them commercially, led to significant revenue growth for St Jude Medical over his career.
Most recently, Sieckhaus held the position of vice president - field clinical affairs for Abbot, where he created a world-class field clinical and monitoring team to support clinical trials across multiple business units within Abbott's Cardiovascular portfolio.
"I am very excited to join this team and look forward to building upon the foundation of the PURE EP system and its capabilities,” Sieckhaus added. “Focusing in the area of electrophysiology by providing better solutions in identifying and treating complex arrhythmias for our clinical customers and patients will be extremely rewarding.”
The PURE EP is an FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology. To date, 75 physicians have completed more than 2150 patient cases with the PURE EP System.
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.
Contact the author at stephen.gunnion@proactiveinvestors.com